Aktienanalyse zu MaxCyte Inc (MXCT)

KI-Analyse of MaxCyte Inc (MXCT)

Halten

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.

Bewertungskennzahlen

Das aktuelle erwartete KGV von MaxCyte Inc (MXCT) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -13.28.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

-13.28

Aktuelles P/E

0.00

Überbewertet

-3.68

Unterbewertet

-22.87

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

-9.98

Aktuelles EV/EBITDA

-3.07

Überbewertet

1.46

Unterbewertet

-21.43

Erwartetes KUV

Unterbewertet

5J-Durchschnitt P/S

9.43

Aktuelles P/S

3.86

Überbewertet

14.36

Unterbewertet

4.49

Alphio-AI-Kursszenarien für MXCT

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%MXCT

$2.88

Szenariopreis

B

Basis

Basis · 50%MXCT

$2.21

Szenariopreis

B

Bärisch

Bärisch · 25%MXCT

$1.63

Szenariopreis

Whales, die MXCT halten

A

Apollo Global Management, Inc.

+ HältMXCT

-2.44%

3-Monats-Rendite

MXCT FAQ – beantwortet von Alphio AI

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.